Applications of SELDI-MS technology in oncology.
Considerable interest, speculation and controversy have been generated utilising surface-enhanced laser desorption/ionization in conjunction with mass spectrometry (SELDI-MS) for the diagnosis, prognosis and therapeutic monitoring of cancer and offers an attractive approach to cancer biomarker discovery from tissues and biological fluids. This technology utilises a combination of mass spectrometry and chromatography to facilitate protein profiling of complex biological mixtures. Compared to some other more traditional proteomic platforms, such as 2D polyacrylamide gel electrophoresis, it has a high-throughput capability and can resolve low-mass proteins. However, a considerable number of challenging issues related to the design of studies, including reproducibility, sensitivity, specificity, variation in sample collection, processing and storage, have been reported as problematic with this technology; albeit some of these concerns could perhaps also be lauded against other proteomic approaches that have attempted to address complex protein mixtures, such as plasma. Applications, successes and limitations of SELDI-MS in both clinical and basic science arenas will be reviewed in this article.
Whelan
L C
LC
UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Ireland.
Power
K A R
KA
McDowell
D T
DT
Kennedy
J
J
Gallagher
W M
WM
D000818:Animals; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008495:Medical Oncology; D009367:Neoplasm Staging; D009369:Neoplasms / Q000737:chemistry / Q000175:diagnosis / Q000601:surgery; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000295:instrumentation* / Q000379:methods*